A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis.
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2014
At a glance
- Drugs House dust mite allergy immunotherapy subcutaneous HAL Allergy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors HAL Allergy
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Mar 2012 This trial is expected to be completed in the beginning of 2013, according to a HAL Allergy media release.
- 20 Mar 2012 Status changed from recruiting to active, no longer recruiting, according to a HAL Allergy media release.